Premium
P4‐388: TRAILBLAZER‐ALZ (NCT03367403): A PHASE 2 DISEASE‐MODIFICATION COMBINATION THERAPY TRIAL TARGETING MULTIPLE MECHANISMS OF ACTION ALONG THE AMYLOID PATHWAY
Author(s) -
Irizarry Michael C.,
Fleisher Adam S.,
Hake Ann Marie,
Liu Peng,
Shcherbinin Sergey,
DeMattos Ronald B.,
Mintun Mark A.
Publication year - 2018
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2018.07.212
Subject(s) - biomarker , medicine , dosing , amyloid (mycology) , amyloid precursor protein , clinical trial , pharmacology , humanized antibody , antibody , disease , alzheimer's disease , pathology , immunology , chemistry , biochemistry , monoclonal antibody